Navigation Links
Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York.   

The live presentation takes place on Monday, February 13 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences Reports Third Quarter 2011 Results
2. Neurocrine Biosciences Reports Second Quarter 2011 Results
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
5. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
6. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
8. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
9. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
10. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... ... , ... In the past three years, the National Science Foundation (NSF) has ... School of Mines & Technology that expands human understanding of the microbial world. ... slimy and yet strong layer which is commonly known as a biofilm. , The ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a ... announces today that the U.S. Patent and Trademark Office (USPTO) and European Patent ... drug class recommendations for hypertension treatment. , The patent applies to Geneticure’s ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... was co-located with the China Focus @ Biotech Week Boston, a forum organized ... and collaborations in healthcare innovation. , After a careful process of evaluation, twelve ...
(Date:9/11/2019)... ... September 10, 2019 , ... Catalent, ... drugs, biologics, gene therapies, and consumer health products, today announced that Alex Haig, ... the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18-19, 2019. , ...
Breaking Biology Technology:
(Date:10/4/2019)... NEW YORK (PRWEB) , ... October 03, 2019 , ... ... the genome that cells hand down from one generation to the next. In a ... mutations can modulate the activity of this enzyme, leading to cancers and other diseases. ...
(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, Inc ... an FDA approved clinical trial for stem cell treatment of knee osteoarthritis . ... the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, ...
(Date:9/30/2019)... , ... September 30, 2019 , ... ... focused on molecular manufacturing and other transformative technologies, announced the winners for the ... Experiment and the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 ...
Breaking Biology News(10 mins):